Alluvi, previously BI 4744, represents a promising advance in obesity care. This dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates impressive results in patient https://bookmarkingace.com/story22171546/alluvi-a-in-depth-investigation-into-retatrutide-s-prospects